#USA #New Orleans #Kahn Swick #Semler Scientific #SMLR

Investigation of Semler Scientific Sale

In a noteworthy turn of events for investors and stakeholders, former Attorney General of Louisiana, Charles C. Foti, Jr., along with the law firm Kahn Swick & Foti, LLC (KSF), is currently scrutinizing the proposed sale of Semler Scientific, Inc. (NASDAQ: SMLR) to Strive, Inc. (NASDAQ: ASST). This investigation delves into whether the terms of the transaction adequately reflect the value of Semler Scientific and the fairness of the process leading to this potential merger.

The details surrounding the proposed transaction indicate that shareholders of Semler Scientific will be compensated with 21.05 Class A common shares of Strive for every share of Semler they hold. This exchange ratio prompts questions about whether it truly represents the fair market value of the company.

What Are The Concerns?

The inquiry from KSF is grounded in the necessity to ensure that Semler Scientific’s stakeholders are receiving a fair deal. A comprehensive look at the price offered in a sale is crucial, as underpricing can lead to significant losses for investors, and potentially affect the company's future growth and stability.

Foti, along with his firm's expertise, is actively assessing whether shareholders are being treated fairly and are receiving what their holdings are worth. They are urging any stakeholders who may feel that the transaction undervalues Semler to get in touch, encouraging open communication regarding their legal rights in light of this proposed sale.

How Investors Can Respond

If investors believe that this proposed sale does not meet the fair value threshold, they are invited to contact Lewis S. Kahn, Managing Partner at KSF. Stakeholders can reach out via email or by calling their toll-free number. This is an important opportunity for investors to voice their concerns and seek guidance on their rights under the current circumstances.

Inquiries can be directed to Kahn Swick & Foti through their official communication channels. Interested parties are encouraged to share their perspectives and concerns regarding the proposed transfer and to understand their options moving forward.

Looking Ahead

As this situation unfolds, all eyes will be on the investigation led by Foti and KSF. This examination could have significant implications for both Semler Scientific's current investors and the company’s future direction in the healthcare industry.

It is imperative for stakeholders to remain informed and engaged as developments in this case emerge. Those interested in the future of Semler Scientific should continue monitoring updates, as the outcome of this investigation may very well influence investment decisions and company strategies in the long run.

For additional information about the case and ongoing updates, investors are directed to visit KSF's official website, which provides further resources and contact information.

In conclusion, this proactive stance by former Attorney General Foti and KSF underscores the importance of due diligence and advocacy in financial transactions, making clear the critical role legal oversight plays in safeguarding investor interests in significant corporate changes.